Overcoming AAV manufacturing bottlenecks: A scalable approach with stable producer cell lines

As gene therapy moves beyond rare diseases, the gene therapy field faces a common challenge: how to scale AAV manufacturing efficiently. Transient transfection methods while effective at lower scales, often fall short when higher doses and larger patient populations are involved slowing down clinical progress and increasing costs.

In this webinar, we explore how stable AAV producer cell lines can help address these limitations by offering a cost-effective and scalable approach to AAV production.

What you will learn:
• Current market trends and challenges with AAV gene therapy
• How stable producer cell lines can support high-yield vector production for various serotypes and transgenes
• How performance of these cell lines can be further pushed >10 fold increases in genomic titers and improved vector quality when combined with process intensification workflows.

Learn more about the ELEVECTA™ producer cell line:
https://www.cytivalifesciences.com/shop/cell-culture-and-fermentation/cell-lines/elevecta-producer-cell-line-p-42420